Table 2 Types and status of cancers in patients with neutropenic pneumonia
Variables | β-lactam group (n = 72) | Combination group (n = 93) | P-value |
|---|---|---|---|
Type of cancer | |||
Head and neck | 3 (4.2%) | 1 (1.1%) | 0.319 |
Lung | 36 (50.0%) | 38 (40.9%) | 0.242 |
Breast | 7 (9.7%) | 12 (12.9%) | 0.526 |
Esophageal and gastric | 8 (11.1%) | 6 (6.5%) | 0.287 |
Colorectal | 1 (1.4%) | 5 (5.4%) | 0.233 |
Hepatobiliary and pancreatic | 0 (0.0%) | 3 (3.2%) | 0.258 |
Bladder | 1 (1.4%) | 5 (5.4%) | 0.233 |
Prostate | 0 (0.0%) | 4 (4.3%) | 0.133 |
Melanoma and sarcoma | 1 (1.4%) | 5 (5.4%) | 0.233 |
Lymphoma and myeloma | 15 (20.8%) | 13 (14.0%) | 0.245 |
Cancer status | |||
Curative setting | 32 (44.4%) | 35 (37.6%) | 0.377 |
Neoadjuvant and adjuvant | 12 (16.7%) | 20 (21.5%) | 0.436 |
Definitive | 20 (27.8%) | 15 (16.1%) | 0.069 |
Palliative settinga | 40 (55.6%) | 58 (62.4%) | 0.377 |
Complete response | 1 (2.5%) | 0 (0.0%) | 0.436 |
Partial response | 2 (5.0%) | 4 (6.9%) | 0.697 |
Stable disease | 0 (0.0%) | 4 (6.9%) | 0.133 |
Progressed or relapse | 22 (55%) | 31 (53.4%) | 0.705 |
Before evaluation | 15 (37.5%) | 19 (32.8%) | 0.949 |